• Something wrong with this record ?

Pulmonary alveolar proteinosis: Clinical and morphological overview of a rare disease associated with macrophage dysfunction

B. Javorská, R. Slivka, B. Durcová, A. Vrbenská, J. Škarda, J. Vecanová, N. Hvizdošová, M. Makovická, V. Kamarád, J. Muri

. 2025 ; 44 (1) : 1-11. [pub] -

Language English Country Slovakia

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25010398

Pulmonary alveolar proteinosis (PAP) is a rare disease characterised by excessive accumulation of surfactant components in alveolar macrophages, alveoli, and peripheral airways. The accumulation of surfactant is associated with only a minimal inflammatory response but can lead to the development of pulmonary fibrosis. Three clinical forms of PAP are distinguished - primary, secondary and congenital. In recent years, significant findings have helped to clarify the ethiology and pathogenesis of the disease. Apart from impaired surfactant protein function, a key role in the development of PAP is played by signal pathway of granulocyte and macrophage colonies stimulating growth factor (GM-CSF) which is necessary for the functioning of alveolar macrophages and for surfactant homeostasis. Surfactant is partially degraded by alveolar macrophages that are stimulated by GM-CSF. The role of GM-CSF has been shown especially in primary PAP, which is currently considered an autoimmune disease involving the development of GM-CSF neutralising autoantibodies. Clinically, the disease may be silent or manifest with dyspnoeic symptoms triggered by exertion and cough. However, there is a 10 to 15% rate of patients who develop respiratory failure. Total pulmonary lavage is regarded as the standard method of treatment. In addition, recombinant human GM-CSF has been studied as a prospective therapy for the treatment of PAP.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010398
003      
CZ-PrNML
005      
20250429134623.0
007      
ta
008      
250415s2025 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/gpb_2024038 $2 doi
035    __
$a (PubMed)39815895
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Javorská, Brigita $u Second Department of Pneumology and Phthisiology, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery in Vyšné Hágy, Vysoké Tatry, Slovakia
245    10
$a Pulmonary alveolar proteinosis: Clinical and morphological overview of a rare disease associated with macrophage dysfunction / $c B. Javorská, R. Slivka, B. Durcová, A. Vrbenská, J. Škarda, J. Vecanová, N. Hvizdošová, M. Makovická, V. Kamarád, J. Muri
520    9_
$a Pulmonary alveolar proteinosis (PAP) is a rare disease characterised by excessive accumulation of surfactant components in alveolar macrophages, alveoli, and peripheral airways. The accumulation of surfactant is associated with only a minimal inflammatory response but can lead to the development of pulmonary fibrosis. Three clinical forms of PAP are distinguished - primary, secondary and congenital. In recent years, significant findings have helped to clarify the ethiology and pathogenesis of the disease. Apart from impaired surfactant protein function, a key role in the development of PAP is played by signal pathway of granulocyte and macrophage colonies stimulating growth factor (GM-CSF) which is necessary for the functioning of alveolar macrophages and for surfactant homeostasis. Surfactant is partially degraded by alveolar macrophages that are stimulated by GM-CSF. The role of GM-CSF has been shown especially in primary PAP, which is currently considered an autoimmune disease involving the development of GM-CSF neutralising autoantibodies. Clinically, the disease may be silent or manifest with dyspnoeic symptoms triggered by exertion and cough. However, there is a 10 to 15% rate of patients who develop respiratory failure. Total pulmonary lavage is regarded as the standard method of treatment. In addition, recombinant human GM-CSF has been studied as a prospective therapy for the treatment of PAP.
650    12
$a plicní alveolární proteinóza $x patologie $7 D011649
650    _2
$a lidé $7 D006801
650    12
$a faktor stimulující granulocyto-makrofágové kolonie $x metabolismus $7 D016178
650    12
$a vzácné nemoci $x patologie $7 D035583
650    12
$a alveolární makrofágy $x imunologie $x patologie $7 D016676
650    _2
$a zvířata $7 D000818
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Slivka, Róbert $u Second Department of Pneumology and Phthisiology, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery in Vyšné Hágy, Vysoké Tatry, Slovakia
700    1_
$a Durcová, Barbora $u Second Department of Pneumology and Phthisiology, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery in Vyšné Hágy, Vysoké Tatry, Slovakia $u First Department of Pneumology and Phthisiology, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery in Vyšné Hágy, Vysoké Tatry, Slovakia
700    1_
$a Vrbenská, Adela $u Department of Pathology, National Institute for Tuberculosis, Lung Diseases, and Thoracic Surgery in Vyšné Hágy, Vysoké Tatry, Slovakia
700    1_
$a Škarda, Jozef $u Institute of Clinical and Molecular Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000281529453 $7 xx0098446
700    1_
$a Vecanová, Janka $u Department of Anatomy of the Faculty of Medicine of Pavol Jozef Šafárik University in Košice, Slovakia $1 https://orcid.org/0000000306239023
700    1_
$a Hvizdošová, Natália $u Department of Anatomy of the Faculty of Medicine of Pavol Jozef Šafárik University in Košice, Slovakia $1 https://orcid.org/000000022052654x
700    1_
$a Makovická, Mária $u Institute of Histology and Embryology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Cancer Research Institute, Biomedical Research Centre of the Slovak Academy of Sciences, Bratislava, Slovakia $1 https://orcid.org/0009000653021421
700    1_
$a Kamarád, Vojtěch $u Institute of Histology and Embryology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0009000653021421
700    1_
$a Muri, Jozef $u Institute of Histology and Embryology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Centre for Thoracic Surgery, National Institute for Tuberculosis, Lung Diseases, and Thoracic Surgery in Vyšné Hágy, Vysoké Tatry, Slovakia $1 https://orcid.org/0009000653021421
773    0_
$w MED00001896 $t General physiology and biophysics $x 0231-5882 $g Roč. 44, č. 1 (2025), s. 1-11
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39815895 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134619 $b ABA008
999    __
$a ok $b bmc $g 2311635 $s 1247479
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 44 $c 1 $d 1-11 $e - $i 0231-5882 $m General physiology and biophysics $n Gen Physiol Biophys $x MED00001896
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options